Small Activating RNAs — a Novel Therapeutic Class of Oligonucleotides

SMi reports: Understanding the principles of RNA activation and possibilities of therapeutic benefit at Oligonucleotide Therapeutics and Delivery Conference

LONDON, UNITED KINGDOM, July 6, 2021 /EINPresswire.com/ -- Engage in the latest innovations of oligonucleotide therapeutics with insights into immunochemotherapeutics, ocular indications and Duchenne Muscular Dystrophy. Deepen your understanding of crucial delivery methods and available platforms for non-hepatocytic delivery.

Download a copy of your brochure to find out who will be speaking at the upcoming conference in September www.oligonucleotide.co.uk/pr5ein

EMERGING DELIVERY SOLUTIONS

Targeted Delivery of C/EBPa-saRNA by RNA Aptamers

•Understanding the principles of RNA activation and possibilities of therapeutic benefit
•Harnessing small activating RNAs for the treatment of Pancreatic ductal adenocarcinoma
•Evaluating aptamers and appropriate means of targeted delivery
•Looking at lessons learnt from using saRNA for oncological purposes
Nagy Habib, Professor of Surgery, Imperial College, Co-founder MiNA therapeutics, Imperial College London

Small activating RNAs — a novel therapeutic class of oligonucleotides

•Description of saRNA technology to upregulate transcription and broad applicability to a range of therapeutic targets
•Generation of a lead candidate saRNA to HNF4a for liver disease

•Update on MiNA's lead saRNA clinical agent MTL-CEBPA – Clinical PD and efficacy
Matthew Catley, Research Director, MiNa Therapeutics Ltd

The tool-box approach to improve the performance of siRNA-platform technology

•Interplay of design and function
•Stability and duration of action
•Linker design and valency of ligands
•Is there room for additional improvements?
Adrien Weingartner, Principal Scientist, Group Leader Drug Delivery, Silence Therapeutics

Clinical development of AsiDNA, a first in class decoy agonist oligonucleotide targeting DNA damage response in tumor cells

•Introduction to platON™: proprietary chemistry platform based on a library of decoy agonist oligonucleotides which generates disruptive compounds acting on intracellular DNA-binding targets
•Introduction to AsiDNA the leading decoy agonist generated from platON and targeting DNA damage response function
•Recent preclinical highlights: AsiDNA abrogates resistance to multiple anti-cancer targeted therapies
•Recent clinical development of AsiDNA
•Outlining next steps of clinical development
Wael Jdey, Head of Biology, Onxeo S.A.

Register online: www.oligonucleotide.co.uk/pr5ein

Proudly Sponsored by ChemGenes | Genscript | Tosoh Bioscience

SMi Group offer direct access to key decision makers through tailored sponsorship and exhibitor packages. For more details and all delegate enquiries please contact Alia Malick on +44 (0)20 7827 6168. For media queries please contact Jinna Sidhu at hsidhu@smi-online.co.uk or call +44 (0)20 7827 6088.

--- END---

About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical

industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Jinna Sidhu
SMi Group
+44 (0) 207 827 6088
email us here
Visit us on social media:
Twitter
LinkedIn
